Revance Therapeutics, Inc.

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 761330109 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Glazer Capital, LLC 13G/A Amendment 1	0%	0	13G/A Amendment 1	5/15/2025 Event 3/31/2025
Glazer Capital, LLC	0%	0
Paul J. Glazer	0%	0
Beryl Capital Management LLC 13G/A Amendment 1	0%	0	13G/A Amendment 1	5/15/2025 Event 3/31/2025
Beryl Capital Management LLC	0%	0
Beryl Capital Management LP	0%	0
Beryl Capital Partners II LP	0%	0
David A. Witkin	0%	0
JPMorgan Chase & Co 13G/A Amendment 1	0%	0	13G/A Amendment 1	3/6/2025 Event 2/28/2025
Palo Alto Investors LP 13G/A Amendment 4	1.5%	1,611,787	13G/A Amendment 4	2/13/2025 Event 9/30/2024
Patrick Lee, MD	1.5%	1,611,787
Anthony Joonkyoo Yun, MD	1.5%	1,611,787
Palo Alto Investors LP	1.5%	1,611,787
Pai LLC	1.5%	1,611,787
JPMorgan Chase & Co 13G	5.4%	5,686,631	13G	2/11/2025 Event 12/31/2024
Glazer Capital, LLC 13G	6.9%	7,210,121	13G	2/6/2025 Event 1/30/2025
Glazer Capital, LLC	6.9%	7,210,121
Paul J. Glazer	6.9%	7,210,121
Teoxane SA 13D/A Amendment 4	6.2%	6,550,800	13D/A Amendment 4	1/30/2025 Event 1/30/2025
Beryl Capital Management LLC 13G	6.1%	6,359,570	13G	1/10/2025 Event 1/2/2025
Beryl Capital Management LLC	6.1%	6,359,570
Beryl Capital Management LP	6.1%	6,359,570
Beryl Capital Partners II LP	5.3%	5,589,328
David A. Witkin	6.1%	6,359,570
Teoxane SA 13D/A Amendment 3	6.2%	6,550,800	13D/A Amendment 3	1/6/2025 Event 1/6/2025
Teoxane SA 13D/A Amendment 2	6.2%	6,550,800	13D/A Amendment 2	12/19/2024 Event 12/19/2024
Franklin Resources, Inc. 13G/A Amendment 1	4.6%	4,784,658	13G/A Amendment 1	10/31/2024 Event 9/30/2024
Franklin Resources, Inc.	4.6%	4,784,658
Charles B. Johnson	0%	0
Rupert H. Johnson, Jr.	0%	0

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2025 Q1	2	86.1 k	$425 k	$0
2024 Q4	200	82.0 M	$249 M	$23.5 M
2024 Q3	229	83.4 M	$432 M	$8.42 M
2024 Q2	190	85.3 M	$219 M	$1.28 M
2024 Q1	210	88.8 M	$439 M	$5.31 M
2023 Q4	224	78.7 M	$692 M	$16.4 M
2023 Q3	220	77.9 M	$893 M	$19.1 M
2023 Q2	246	83.1 M	$2.10 B	$39.8 M
2023 Q1	248	76.7 M	$2.47 B	$61.9 M
2022 Q4	218	75.9 M	$1.40 B	$191 M
2022 Q3	205	67.7 M	$1.82 B	$298 M
2022 Q2	178	56.0 M	$774 M	$20.5 M
2022 Q1	171	54.6 M	$1.06 B	$29.5 M
2021 Q4	173	53.1 M	$867 M	$19.8 M
2021 Q3	166	54.9 M	$1.53 B	$14.9 M
2021 Q2	169	54.1 M	$1.60 B	$16.5 M
2021 Q1	156	54.8 M	$1.53 B	$18.1 M
2020 Q4	165	53.4 M	$1.51 B	$20.3 M
2020 Q3	165	49.5 M	$1.25 B	$17.4 M
2020 Q2	150	50.6 M	$1.23 B	$5.11 M
2020 Q1	138	49.5 M	$732 M	$1.71 M
2019 Q4	146	51.6 M	$838 M	$3.38 M
2019 Q3	117	42.6 M	$554 M	$2.37 M
2019 Q2	128	43.7 M	$566 M	$4.41 M
2019 Q1	120	41.7 M	$657 M	$1.87 M
2018 Q4	108	35.6 M	$741 M	$1.34 M
2018 Q3	121	34.7 M	$863 M	$3.20 M
2018 Q2	119	35.2 M	$965 M	$4.19 M
2018 Q1	127	34.4 M	$1.06 B	$4.28 M
2017 Q4	131	35.0 M	$1.25 B	$24.7 M
2017 Q3	91	27.4 M	$755 M	$1.41 M
2017 Q2	91	27.5 M	$727 M	$1.66 M
2017 Q1	83	26.4 M	$549 M	$1.03 M
2016 Q4	85	26.3 M	$544 M	$364 k
2016 Q3	77	28.6 M	$464 M	$184 k
2016 Q2	86	28.8 M	$391 M	$457 k
2016 Q1	90	27.3 M	$477 M	$1.08 M
2015 Q4	112	27.2 M	$931 M	$4.83 M
2015 Q3	82	21.7 M	$655 M	$4.98 M
2015 Q2	89	20.5 M	$655 M	$269 k
2015 Q1	72	20.6 M	$426 M	$896 k
2014 Q4	68	19.8 M	$335 M	$0
2014 Q3	82	15.7 M	$303 M	$0
2014 Q2	100	16.7 M	$567 M	$0
2014 Q1	67	11.9 M	$376 M	$0